SynAct Pharma Beheer

Beheer criteriumcontroles 0/4

De CEO SynAct Pharma is Jeppe Ovlesen, benoemd in Mar2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.033% van de aandelen van het bedrijf, ter waarde SEK 118.77K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 0.7 jaar.

Belangrijke informatie

Jeppe Ovlesen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Analyse CEO-vergoeding

Hoe is Jeppe Ovlesen's beloning veranderd ten opzichte van SynAct Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 155m
Jun 30 2024	n/a	n/a	-SEK 166m
Mar 31 2024	n/a	n/a	-SEK 191m
Dec 31 2023	n/a	n/a	-SEK 216m
Sep 30 2023	n/a	n/a	-SEK 156m
Jun 30 2023	n/a	n/a	-SEK 148m
Mar 31 2023	n/a	n/a	-SEK 129m
Dec 31 2022	SEK 4m	SEK 3m	-SEK 99m
Sep 30 2022	n/a	n/a	-SEK 95m
Jun 30 2022	n/a	n/a	-SEK 89m
Mar 31 2022	n/a	n/a	-SEK 78m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 69m
Sep 30 2021	n/a	n/a	-SEK 52m
Jun 30 2021	n/a	n/a	-SEK 41m
Mar 31 2021	n/a	n/a	-SEK 35m
Dec 31 2020	SEK 2m	SEK 2m	-SEK 27m
Sep 30 2020	n/a	n/a	-SEK 29m
Jun 30 2020	n/a	n/a	-SEK 24m
Mar 31 2020	n/a	n/a	-SEK 23m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 24m
Sep 30 2019	n/a	n/a	-SEK 20m
Jun 30 2019	n/a	n/a	-SEK 23m
Mar 31 2019	n/a	n/a	-SEK 24m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 23m
Jun 30 2018	n/a	n/a	-SEK 19m
Mar 31 2018	n/a	n/a	-SEK 15m
Dec 31 2017	SEK 2m	SEK 2m	-SEK 15m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Jeppe redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Swedish markt.

Compensatie versus inkomsten: De vergoeding van Jeppe is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jeppe Ovlesen (62 yo)

less than a year

Tenure

SEK 3,656,000

Compensatie

Mr. Jeppe Ovli Ovlesen, EE, MBA, serves CEO & Director of SynAct Pharma AB since March 20, 2024. He serves as Director at Cereno Scientific AB (publ) since November 07, 2023. He served as the Chief Execut...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeppe Ovlesen	CEO & Director	less than a year	SEK 3.66m	0.033% SEK 118.8k
Bjorn Westberg	Chief Financial Officer	1.4yrs	geen gegevens	geen gegevens
Thomas Boesen	Chief Operating Officer	3.8yrs	geen gegevens	0.045% SEK 159.8k
James Knight	Chief Business Officer	3.8yrs	geen gegevens	geen gegevens
Kristen Harting	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van SYNACT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeppe Ovlesen	CEO & Director	less than a year	SEK 3.66m	0.033% SEK 118.8k
Sten Scheibye	Director	less than a year	geen gegevens	geen gegevens
Vibeke Strand	Member of Clinical Advisory Board	less than a year	geen gegevens	geen gegevens
Mauro Perretti	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anders Kronborg	Chairman of Board	less than a year	geen gegevens	geen gegevens
Sten Sorensen	Director	less than a year	geen gegevens	geen gegevens
Ravi Rao	Member of Clinical Advisory Board	less than a year	geen gegevens	geen gegevens
Roy Fleischmann	Member of Clinical Advisory Board	less than a year	geen gegevens	geen gegevens
Mauro Teixeira	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SYNACT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw bestuur.

SynAct Pharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Chief Operating Officer recently bought kr1.9m worth of stock

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Recent updates

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Chief Operating Officer recently bought kr1.9m worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189

Chief Medical Officer Thierry Duvauchelle has left the company

Synact Pharma AB Announces Positive Data from A Phase 2A Trial of Ap1189 in Covid-19 Infected Patients

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

SynAct Pharma Updates Phase II study with AP1189

Synact Pharma Expands Ap1189 Begin Study in Rheumatoid Arthritis Uk Version

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

SynAct Pharma AB Initiates Dosing in Part 2 of the Clinical Phase II Study with AP1189 in Covid-19 Infected Patients UK Version

Chief Financial Officer recently sold kr2.9m worth of stock

SynAct Pharma AB Names James Knight as Chief Business Officer